# Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma

> **NCT02965157** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Beijing Biohealthcare Biotechnology Co.,Ltd** · enrollment: 15 (estimated)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **BIOLOGICAL:** CART20

## Key facts

- **NCT ID:** NCT02965157
- **Lead sponsor:** Beijing Biohealthcare Biotechnology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2018-01
- **Final completion:** —
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2016-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02965157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02965157, "Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02965157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*